Context

Inotrem is a leading biotechnology company specialized in the development of immunotherapies for acute and chronic inflammatory diseases.

It has a seasoned management team with complementary experiences in large pharma and biotech companies.

Inotrem’s lead candidate, nangibotide, is a Phase IIb ready compound designed to treat septic shock, the ultimate complication of sepsis, with a mortality rate of 35% in developed countries.

It has the potential to become the first mechanism-based therapy approved in a challenging indication.

Bryan, Garnier & Co was retained to lead a Series B round to finance Phase IIb trial and nangibotide companion diagnostic final development.

The proceeds will also allow Inotrem to further leverage its platform to address chronic inflammatory diseases.

About Inotrem

Inotrem S.A. has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive.

Discover Inotrem

Hervé Ronin

Investment Banking

Romain Ellul

Investment Banking

Sandrine Cailleteau

Investment Banking

Remi Negre

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center